Myelodysplastic syndromes current treatment algorithm 2018

[Current treatment strategies for myelodysplastic syndromes].

Myelodysplastic syndromes (MDS) are myeloid clonal disorders presumably induced by genetic mutations in immature hematopoietic cells. According to the international prognostic scoring system (IPSS or IPSS-R), patients are classified into two groups: lower-risk MDS (LR-MDS) and higher-risk MDS (HR-MDS). A majority of LR-MDS patients manifest refractory cytopenias due to inefficient hematopoiesis...

Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for progression, suggest that myelodysplastic syndromes encompass a multitude of d...

Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes.

No significant relationship exists between the author and the companies/organizations whose products or services may be referenced in this article. T he development of new, more effective treatment strategies for the myelodysplastic syndromes (MDS) has for the first time jettisoned the management approach away from the reliance on supportive measures alone toward one of active intervention. Coi...

Treatment options for myelodysplastic syndromes.

Cancer Control 7 but this approach is unlikely to change the natural history of the disorder. Despite the recent approval of azacitidine, supportive care alone will remain an important treatment option for many patients with MDS. Supportive care consists of transfusions for symptomatic anemia or symptomatic thrombocytopenia, treatment of infections with antibiotics,and growth factors designed t...

Treatment Options in Myelodysplastic Syndromes